Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Risk of tuberculosis in Korean inflammatory bowel disease patients treated with Tumor Necrosis Factor-a (TNF-a) blockers

ABSTRACT: Primary outcome(s): Quantification of the incidence rate of TB in IBD patients treated with TNF-a blockers and compared that with general population rates Study Design: Observational Study Model : Cohort, Time Perspective : Retrospective, Enrollment : 1000, Biospecimen Retention : Not collect nor Archive

DISEASE(S): Diseases Of The Digestive System

PROVIDER: 2509453 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Diagnostic method using cell free DNA to predict the prognosis of patients with colorectal cancer

Project description:Primary outcome(s): Comparative evaluation of the existing cfDNA quantification method based on clinical samples and this method Study Design: Observational Study Model : Cohort, Time Perspective : Prospective, Enrollment : 20, Biospecimen Retention : Collect & Archive- Sample without DNA, Biospecimen Description : serum

| 2513434 | ecrin-mdr-crc

A Construction of Cancer Registry and Prospective Korean Medicinal Cancer Cohort Study in East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University : Focused on Lung, Breast, Stomach, Colorectal, Liver, Uterine and Ovarian Cancers

Project description:Primary outcome(s): Disease-free survival (DFS) Study Design: Observational Study Model : Cohort, Time Perspective : Prospective, Enrollment : 172, Biospecimen Retention : Collect & Archive- Sample without DNA, Biospecimen Description : Whole blood, plasma, WBC, RBC

| 2510317 | ecrin-mdr-crc

The adjusted caprini score is a useful measure for preventing venous thromboembolism

Project description:Primary outcome(s): Incidence of VTE Study Design: Observational Study Model : Case-control, Time Perspective : Retrospective, Enrollment : 1000, Biospecimen Retention : Not collect nor Archive

| 25945 | ecrin-mdr-crc

Serum trefoil factor family 3 as a biomarker in Korean patients with colorectal cancer

Project description:Primary outcome(s): level of serum trefoil factor family 3 Study Design: Observational Study Model : Case-control, Time Perspective : Prospective, Enrollment : 200, Biospecimen Retention : Collect & Archive- Sample without DNA, Biospecimen Description : serum, colonic mucosa tissue

| 2511406 | ecrin-mdr-crc

Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease

Project description:Anti-TNF (tumor necrosis factor) monoclonal antibodies have revolutionized management of Inflammatory bowel disease. Their common features include high efficacy but also immunogenicity and increased infection risk. Since 2013, two generics or biosimilars of the first anti-TNF have been registered in Europe, which long lerm safety profile needs yet to be established. This prospective, multicenter, observational cohort study will assess safety of treatment of anti-TNF monoclonal antibodies in inflammatory bowel disease patients in Poland. Eligible are consecutive patients in whom anti-TNF is started for Crohn’s disease, ulcerative colitis or indeterminate colitis between January 1st, 2014 and December 31st, 2015. Data to be collected include demography, Montreal classification, indication to treatment, previous treatment, operations, extraintestinal manifestations and concomitant diseases. Data on response, tolerability and safety of anti-TNF and on concomitant treatment will be collected. Adverse events logs will be completed. Majority of IBD centres in Poland, pediatric and adult, academic and regional, have agreed to participate in the study. As a result of the study, the frequency of adverse events in a cohort of Polish IBD patients on various anti-TNFs will be established.

| 2161078 | ecrin-mdr-crc

De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

Project description:BACKGROUND/RATIONALE: Treatment outcomes of patients with inflammatory bowel disease (IBD) have improved enormously during the past decade due to the use of anti-tumour necrosis factor (anti-TNF) therapy. As a result, 67 to 91% of paediatric patients and 66% of adult patients is still in sustained remission two years after the initiation of anti-TNF therapy. Prolonged use of anti-TNFs comes with disadvantages such as dose dependent susceptibility to infections and dermatological adverse effects. Preliminary, mostly uncontrolled studies suggest that dose reduction by dosing interval lengthening is a realistic option in a relevant proportion of patients with IBD, provided that intensive follow-up is applied. OBJECTIVE: To evaluate whether a faecal calprotectin (FC) guided strategy of anti-TNF dosing interval lengthening is non-inferior in maintaining remission in patients with IBD, compared with an unchanged dosing interval.

| 2359035 | ecrin-mdr-crc

Whole transcription profile of responders to anti-TNF drugs in pediatric inflammatory bowel disease

Project description:Background: In pediatric inflammatory bowel disease (IBD) up to 30% of patients do not respond to anti-TNF therapy. The aim was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: The study population included 29 responders and 9 non-responders to anti-TNF therapy patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Whole gene expression profiles from total RNA isolated from whole-blood samples of 6 responders and 6 non-responders taken before biologic administration and after 2 weeks were analyzed by RNA next-generation sequencing. The expression of 6 selected genes was measured for validation in all of 38 patients recruited using qPCR; Results: Differentially expressed genes in non-responders versus responders to anti-TNF treatment were identified, 32 prior treatment initiation and 44 after 2 weeks (Log2FC (Fold change)>0.6 o <-0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B and GBP1 were overexpressed in non-responders after 2 weeks of anti-TNF treatment (Log2FC 1.05, 1.21 and 1.08, respectively, p value <0.05,); Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.

2021-01-14 | GSE159034 | GEO

Colorectal cancer and obesity

Project description:Primary outcome(s): Abdominal visceral fat volume;Body mass index Study Design: Observational Study Model : Case-control, Time Perspective : Cross-sectional, Enrollment : 250, Biospecimen Retention : Collect & Archive- Sample with DNA, Biospecimen Description : colorectal cancer

| 2509226 | ecrin-mdr-crc

Multimarker in normal colorectal mucosa to predict occurrence of colorectal neoplasm

Project description:Primary outcome(s): Association of Mulkimarker expression pattern and synchronous neoplasm Study Design: Observational Study Model : Case-control, Time Perspective : Others, Enrollment : 50, Biospecimen Retention : Collect & Archive- Sample with DNA, Biospecimen Description : Tissue sample

| 2508885 | ecrin-mdr-crc

Analgesic efficacy of dexmedetomidine in patients undergoing laparoscopic colorectal cancer surgery

Project description:Primary outcome(s): postoperative pain score Study Design: Observational Study Model : Cohort, Time Perspective : Retrospective, Enrollment : 160, Biospecimen Retention : Not collect nor Archive

| 2514216 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data